fingolimod hydrochloride has been researched along with Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Askari, M; Ghaffary, EM; Ghajarzadeh, M; Ghoshouni, H; Mirmosayyeb, O; Shaygannejad, V | 1 |
| Alping, P; Askling, J; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M | 1 |
| Ackermann, CJ; Berner, F; Diem, S; Flatz, L; Hasan Ali, O; Hundsberger, T; Markert, E; Moulin, A; Müller, J; Müller, S; Pop, OT; Ring, SS | 1 |
| Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL | 1 |
| Anders, RA; Carrera-Haro, MA; Drake, CG; Ghasemzadeh, A; Kochel, CM; Lopez-Bujanda, Z; Mao, W; Marciscano, AE; Meeker, AK; Muroyama, Y; Nirschl, TR; Pardoll, DM; Tam, AJ; Theodros, D; Thoburn, CJ; Uddin, M; Velarde, E | 1 |
| Rommer, PS; Zettl, UK | 1 |
| Cong, ZX; Ji, XJ; Wang, HD; Zhang, L; Zhou, Y; Zhu, JH | 1 |
| Hla, T; Proia, RL | 1 |
| Chen, B; Edinger, AL; Fallegger, D; Fransson, R; Hanessian, S; Huwiler, A; Keebaugh, A; Kleinman, MT; McCracken, AN; McMonigle, RJ; Roy, SG; Selwan, E | 1 |
| Cristóbal, I; García-Foncillas, J; González-Alonso, P; Madoz-Gúrpide, J; Manso, R; Rojo, F | 1 |
| Alshaker, H; Cooper, C; Pchejetski, D; White, C; Winkler, M | 1 |
| Carratù, MR; De Rasmo, D; Reale, A; Signorile, A; Vacca, A | 1 |
| Milstien, S; Paugh, SW; Spiegel, S; Takabe, K | 1 |
| Abdollahi, A; Domhan, S; Zeier, M | 1 |
| Peyruchaud, O | 1 |
| McFadden, G; Werden, SJ | 1 |
| Engelhard, VH; Enriquez, HL; Fu, YX; Thompson, ED | 1 |
| Eshhar, Z; Marcus, A; Waks, T | 1 |
| Hla, T; Obinata, H | 1 |
| Bittman, R; Pyne, NJ; Pyne, S | 1 |
| Lopez, AF; Pitman, MR; Pitson, SM; Woodcock, JM | 1 |
| Huwiler, A; Pfeilschifter, J | 1 |
| Morel, D | 1 |
12 review(s) available for fingolimod hydrochloride and Neoplasms
| Article | Year |
|---|---|
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Incidence; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasms | 2022 |
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Topics: Alemtuzumab; Cladribine; Crotonates; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Neoplasms; Nitriles; Toluidines | 2018 |
FTY720 for cancer therapy (Review).
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; United States; United States Food and Drug Administration | 2013 |
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2015 |
Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Protein Phosphatase 2 | 2016 |
The emerging role of FTY720 (Fingolimod) in cancer treatment.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Neoplasms; Prognosis; Proto-Oncogene Mas; Signal Transduction | 2016 |
Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Topics: Antineoplastic Agents; Biological Products; Bortezomib; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Neoplasms; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt | 2016 |
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Enzyme Activation; Fingolimod Hydrochloride; Humans; Hypersensitivity; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sulfhydryl Compounds | 2008 |
Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer.
Topics: Fingolimod Hydrochloride; Humans; Lysophospholipids; Neoplasms; Propylene Glycols; Receptors, Lysophosphatidic Acid; Receptors, Lysosphingolipid; Sphingosine | 2009 |
Sphingosine 1-phosphate in coagulation and inflammation.
Topics: Animals; Atherosclerosis; Blood Coagulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lymph Nodes; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Tumor Necrosis Factor-alpha | 2012 |
Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sphingosine; Vinyl Compounds | 2011 |
Molecular targets of FTY720 (fingolimod).
Topics: Antineoplastic Agents; Apoptosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
11 other study(ies) available for fingolimod hydrochloride and Neoplasms
| Article | Year |
|---|---|
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Incidence; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Neoplasms; Rituximab; Sweden | 2020 |
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
Topics: Female; Fingolimod Hydrochloride; Humans; Immune Checkpoint Inhibitors; Immunosuppressive Agents; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasms | 2021 |
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines | 2021 |
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Topics: Animals; Cell Line, Tumor; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Interleukin-33; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Radiosurgery; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Tumor Burden; Tumor Microenvironment | 2017 |
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice, Nude; Neoplasms; Pyrrolidines; Receptors, Lysosphingolipid | 2016 |
Immunosuppressive therapy and post-transplant malignancy.
Topics: Azathioprine; Calcineurin Inhibitors; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mycophenolic Acid; Neoplasms; Organ Transplantation; Propylene Glycols; Protein Kinases; Sphingosine; TOR Serine-Threonine Kinases | 2009 |
Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.
Topics: Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Myxoma virus; Neoplasms; Okadaic Acid; Phosphoric Monoester Hydrolases; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sphingosine; TOR Serine-Threonine Kinases; Viral Proteins; Viral Tropism; Virus Replication | 2010 |
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Topics: Adoptive Transfer; Animals; Antigen Presentation; Antigen-Presenting Cells; beta 2-Microglobulin; Carcinoma, Lewis Lung; CD11a Antigen; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Fingolimod Hydrochloride; Granzymes; Hyaluronan Receptors; Immunosuppressive Agents; Integrin alpha4; Interferon-gamma; Lymph Nodes; Lymphocyte Activation; Lysosomal Membrane Proteins; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Monophenol Monooxygenase; Neoplasms; Ovalbumin; Peptide Fragments; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocyte Subsets | 2010 |
Redirected tumor-specific allogeneic T cells for universal treatment of cancer.
Topics: Animals; Antigens, Neoplasm; Cell Separation; Fingolimod Hydrochloride; Flow Cytometry; Graft vs Host Disease; Immunosuppressive Agents; Immunotherapy, Adoptive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Propylene Glycols; Sphingosine; T-Lymphocytes; Transplantation, Homologous | 2011 |
Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.
Topics: Amidohydrolases; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Ceramidases; Ceramides; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Lipid Metabolism; Lysophospholipids; Neoplasms; Neovascularization, Pathologic; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2006 |
[mTOR and FTY 720 inhibitors].
Topics: Cyclosporine; Drug Interactions; Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Hyperlipidemias; Immunosuppressive Agents; Kidney; Neoplasms; Propylene Glycols; Sirolimus; Sphingosine | 2001 |